Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Dec 4, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on improving the diagnosis and classification of liver cancer, specifically a type called hepatocellular carcinoma (HCC). Researchers are studying how certain genetic changes, known as mutations, in tumors can help predict how patients might respond to treatment after surgery. By developing a simple testing method using tissue samples, the goal is to identify which tumors should undergo more detailed genetic testing. This approach aims to save time and resources in the lab while providing better information for doctors to guide treatment decisions.

To participate in this trial, you must be at least 18 years old and have undergone surgery to remove HCC. If you have tissue samples available for testing, you may be eligible to join. Participants can expect to contribute to important research that could lead to better outcomes for future patients with liver cancer. There are no specific exclusions, meaning most patients with the right condition can potentially take part in this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Patients resected for HCC
• • Availability of NGS data
• • Availability of paraffin material for immunohistochemistry investigations
• Exclusion Criteria:
• • None